The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer
Abstract
CONTEXT: The association between menopausal hormone replacement therapy and ovarian cancer is unclear. OBJECTIVE: To determine whether hormone replacement therapy using estrogen only, estrogen-progestin only, or both estrogen only and estrogen-progestin increases ovarian cancer risk. DESIGN: A 1979-1998 cohort study of former participants in the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. SETTING: Twenty-nine US clinical centers. PARTICIPANTS: A total of 44 241 postmenopausal women (mean age at start of follow-up, 56.6 years). MAIN OUTCOME MEASURE: Incident ovarian cancer. RESULTS: We identified 329 women who developed ovarian cancer during follow-up. In time-dependent analyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was significantly associated with ovarian cancer (rate ratio [RR], 1.6; 95% confidence interval [CI], 1.2-2.0). Increasing duration of estrogen-only use was significantly associated with ovarian cancer: RRs for 10 to 19 years and 20 or more years were 1.8 (95% CI, 1.1-3.0) and 3.2 (95% CI, 1.7-5.7), respectively (P value for trend <.001), and we observed a 7% (95% CI, 2%-13%) increase in RR per year of use. We observed significantly elevated RRs with increasing duration of estrogen-only use across all strata of other ovarian cancer risk factors, including women with hysterectomy. The RR for estrogen-progestin use after prior estrogen-only use was 1.5 (95% CI, 0.91-2.4), but the RR for estrogen-progestin-only use was 1.1 (95% CI, 0.64-1.7). The RRs for less than 2 years and 2 or more years of estrogen-progestin-only use were 1.6 (95% CI, 0.78-3.3) and 0.80 (95% CI, 0.35-1.8), respectively, and there was no evidence of a duration response (P value for trend =.30). CONCLUSION: Women who used estrogen-only replacement therapy, particularly for 10 or more years, were at significantly increased risk of ovarian cancer in this study. Women who used short-term estrogen-progestin-only replacement therapy were not at increased risk, but risk associated with short-term and longer-term estrogen-progestin replacement therapy warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk
Schairer, C. (2000) · JAMA · doi:10.1001/jama.283.4.485 · Cited by 1,048
Oral Care Reduces Pneumonia in Older Patients in Nursing Homes
Yoneyama, T., Yoshida, M., Ohrui, T., Mukaiyama, H., Okamoto, H., Hoshiba, K., Ihara, S., Yanagisawa, S., Ariumi, S., Morita, T., et al. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50106.x · Cited by 791
Risch, H. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1774 · Cited by 771
Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women
Rodriguez, C. (2001) · JAMA · doi:10.1001/jama.285.11.1460 · Cited by 424
Persson, I., Yuen, J., Bergkvist, L., & Schairer, C. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960729)67:3<327::aid-ijc4>3.0.co;2-t · Cited by 334
Lau, K.-M., Mok, S. C., & Ho, S.-M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5722 · Cited by 277
Risk of cancer in women receiving hormone replacement therapy
Adami, H., Persson, I., Hoover, R., Schairer, C., & Bergkvist, L. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910440515 · Cited by 267
Risch, H. A., Marrett, L. D., Jain, M., & Howe, G. R. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008937 · Cited by 257
Syed, V., Ulinski, G., Mok, S. C., Yiu, G. K., & Ho, S. (2001) · PubMed · Cited by 243
Purdie, D., Green, A., Bain, C., Siskind, V., Ward, B., Hacker, N., Quinn, M., Wright, G., Russell, P., & Susil, B. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620606 · Cited by 241
Brett, K. M., & Madans, J. H. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009142 · Cited by 241
Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women
Riman, T. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.497 · Cited by 228
Frenkel, H., Harvey, I., & Newcombe, R. G. (2001) · Community Dentistry and Oral Epidemiology · doi:10.1034/j.1600-0528.2001.290408.x · Cited by 213
Brandenberger, A. W., Tee, M. K., & Jaffe, R. B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4788 · Cited by 210
Infectious Complications of Dental and Periodontal Diseases in the Elderly Population
Shay, K. (2002) · Clinical Infectious Diseases · doi:10.1086/339865 · Cited by 207
Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis
Garg, P. (1998) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00139-2 · Cited by 182
Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer
Polychronopoulou, A., Τζώνου, Α., Hsieh, C., Trichopoulos, D., KAPRINIS, G. S., Rebelakos, A., & Toupadaki, N. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550312 · Cited by 140
Schairer, C., Byrne, C., Keyl, P. M., Brinton, L. A., Sturgeon, S. R., & Hoover, R. N. (1994) · Cancer Causes & Control · doi:10.1007/bf01831376 · Cited by 138
Mink, P. J., Folsom, A. R., Sellers, T. A., & Kushi, L. H. (1996) · Epidemiology · doi:10.1097/00001648-199601000-00008 · Cited by 120
A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer
Coughlin, S. S., Giustozzi, A. G., Smith, S. J., & Lee, N. C. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00179-1 · Cited by 119
Menopausal estrogen use and risk of breast cancer
Brinton, L. A., Hoover, R. N., Szklo, M., & Fraumeni, J. F. (1981) · Cancer · Cited by 117
Hormone replacement therapy and risk of epithelial ovarian cancer
Purdie, D. M., Bain, C., Siskind, V., Russell, P. J., Hacker, N. F., Ward, B. G., Quinn, M. A., & Green, A. C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690731 · Cited by 112
Noncontraceptive Estrogen Use and the Occurrence of Ovarian Cancer 1 2
Vecchia, C. L., Liberati, A., & Franceschi, S. (1982) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/69.6.1207 · Cited by 109
Hartge, P. A., Hoover, R. N., McGowan, L., Lesher, L. P., & Norris, H. J. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114902 · Cited by 105
STILBŒSTROL (DIETHYLSTILBESTROL) AND THE RISK OF OVARIAN CANCER
Hoover, R. N., Gray, L., & Fraumeni, J. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90667-5 · Cited by 91
Horn‐Ross, P. L., Whittemore, A. S., Harris, R. B., & Itnyre, J. (1992) · Epidemiology · doi:10.1097/00001648-199211000-00005 · Cited by 82
Hempling, R. E., WONG, C., STEVENPIVER, M., NATARAJAN, N., & Mettlin, C. J. (1997) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(97)00118-x · Cited by 80
Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies
Negri, E., Τζώνου, Α., Beral, V., Λάγιου, Π., Trichopoulos, D., Parazzini, F., Franceschi, S., Booth, M., & Vecchia, C. L. (1999) · International Journal of Cancer · Cited by 79
Pike, M. C., Ross, R. K., & SPICER, D. V. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009515 · Cited by 67
Bias in Breast Cancer Analyses Due to Error in Age at Menopause
Rockhill, B., Colditz, G. A., & ROSNER, B. A. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010220 · Cited by 54
BG-1 ovarian cell line: An alternative model for examining estrogen-dependent growth in vitro
Baldwin, W. S., Curtis, S. W., Cauthen, C. A., Risinger, J. I., Korach, K. S., & Barrett, J. C. (1998) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-996-0015-9 · Cited by 49
A Practical Guide to Prescribing Hormone Replacement Therapy
McKinney, K. A., & Thompson, W. (1998) · Drugs · doi:10.2165/00003495-199856010-00005 · Cited by 42
Cited by
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990
Estrogen–gut microbiome axis: Physiological and clinical implications
Baker, J. M., Al-Nakkash, L., & Herbst-Kralovetz, M. M. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.06.025 · Cited by 993
Ovarian cancer and hormone replacement therapy in the Million Women Study
Beral, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60534-0 · Cited by 937
Ovarian cancer in the world: epidemiology and risk factors
Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019) · International Journal of Women's Health · doi:10.2147/ijwh.s197604 · Cited by 912
Metadata
- Authors
- Lacey, Jr.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-17
- Volume
- 288
- Issue
- 3
- Pages
- 334
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1995055473
- Cited by
- 606
- References
- 34
- FWCI
- 35.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.